{"news_desk": "SundayBusiness", "print_page": "15", "section_name": "Business Day", "subsection_name": "Mutual Funds", "byline": {"contributor": "", "original": "By PAUL J. LIM", "person": [{"middlename": "J.", "firstname": "Paul", "lastname": "LIM", "rank": 1, "role": "reported", "organization": ""}]}, "abstract": "Exchange-traded funds have benefited so far in 2015 from health care companies, which have gained some 7 percent in otherwise flat quarter; analysts attribute sector's resurgence to drop-off in patent expirations, stabilized earnings and increasing confidence in biotech.", "type_of_material": "News", "word_count": "1010", "lead_paragraph": "The sector\u2019s resurgence has been attributed to the stabilization of earnings in big pharmaceutical companies and a shift in perceptions of biotech.", "pub_date": "2015-04-12T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Health Care Has Been This Quarter\u2019s Elixir for Stock Funds", "print_headline": "This Quarter\u2019s Elixir: Health Care"}, "snippet": "The sector\u2019s resurgence has been attributed to the stabilization of earnings in big pharmaceutical companies and a shift in perceptions of biotech.", "multimedia": [{"height": 126, "url": "images/2015/04/12/business/12-HEALTH-1/12-HEALTH-1-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/04/12/business/12-HEALTH-1/12-HEALTH-1-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 75, "url": "images/2015/04/12/business/12-HEALTH-1/12-HEALTH-1-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/04/12/business/12-HEALTH-1/12-HEALTH-1-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/04/12/business/mutfund/this-quarters-elixir-health-care.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Exchange Traded Funds", "name": "subject"}, {"rank": "2", "is_major": "N", "value": "Mutual Funds", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "Biotechnology and Bioengineering", "name": "subject"}, {"rank": "4", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Medicine and Health", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Standard & Poor's 500-Stock Index", "name": "subject"}, {"rank": "7", "is_major": "N", "value": "Stocks and Bonds", "name": "subject"}], "blog": [], "_id": "5528f83b38f0d855b3a952ea", "source": "The New York Times"}